

Steve Y Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8485658/publications.pdf>

Version: 2024-02-01

36
papers

2,040
citations

586496

16
h-index

466096

32
g-index

36
all docs

36
docs citations

36
times ranked

2576
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 565-574.	1.3	378
2	Biodistribution, Tumor Detection, and Radiation Dosimetry of ¹⁸ F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1883-1891.	2.8	264
3	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 411-419.	1.3	202
4	¹⁸ F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	2.8	180
5	Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. <i>Clinical Cancer Research</i> , 2021, 27, 3674-3682.	3.2	179
6	Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 5-15.	0.6	165
7	Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2015, 29, 877-882.	1.2	152
8	Comparison of Prostate-Specific Membrane Antigen-Based ¹⁸ F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 46-53.	2.8	111
9	Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. <i>Pediatric Radiology</i> , 2019, 49, 1545-1564.	1.1	71
10	[124I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. <i>Nuclear Medicine and Biology</i> , 2016, 43, 273-279.	0.3	47
11	Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 187, 39-48.	1.2	44
12	Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAH): Methodology statement. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26421.	0.8	35
13	Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies. <i>Tomography</i> , 2015, 1, 81-84.	0.8	31
14	Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. <i>Radiology</i> , 2018, 287, 303-312.	3.6	25
15	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 518-531.	2.5	25
16	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	2.8	24
17	PET Imaging for Breast Cancer. <i>Radiologic Clinics of North America</i> , 2021, 59, 725-735.	0.9	15
18	Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29212.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 989-998.	3.3	12
20	In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. <i>Journal of Nuclear Medicine</i> , 2006, 47, 837-45.	2.8	11
21	The Role of PET in the Evaluation of Musculoskeletal Infections. <i>Seminars in Musculoskeletal Radiology</i> , 2014, 18, 166-174.	0.4	8
22	A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 458-463.	0.4	8
23	US Trainee and Faculty Perspectives on Exposure to Nuclear Medicine/Molecular Imaging During Medical School. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 585-591.	0.6	7
24	Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28365.	0.8	5
25	Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7504-7504.	0.8	5
26	Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis. <i>Blood</i> , 0, , .	0.6	4
27	Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma. <i>EJNMMI Physics</i> , 2017, 4, 22.	1.3	3
28	Proposed Criteria Positions PSMA PET for the Future. <i>Journal of Nuclear Medicine</i> , 2018, 59, 466-468.	2.8	3
29	To Hold or Not to Hold Metformin for FDG PET Scans: That Is the Question. <i>Radiology</i> , 2018, 289, 426-427.	3.6	3
30	Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 890-900.	0.4	3
31	PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS267-TPS267.	0.8	2
32	18f-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). A Preliminary Retrospective Analysis of Children's Oncology Group (COG) AHOD0031. <i>Blood</i> , 2012, 120, 1530-1530.	0.6	2
33	Amyloid deposition on positron emission tomography correlates with severity of perioperative delirium: a case-control pilot study. <i>British Journal of Anaesthesia</i> , 2022, , .	1.5	2
34	Clinical Translation of Molecular Imaging Probes. , 2012, , 1041-1065.		1
35	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)â€™s subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.. <i>Journal of Clinical Oncology</i> , 2021, 39, 33-33.	0.8	0
36	Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 74-74.	0.8	0